Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists
出版年份 2021 全文链接
标题
Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists
作者
关键词
-
出版物
Journal of Movement Disorders
Volume 14, Issue 3, Pages 193-203
出版商
The Korean Movement Disorder Society
发表日期
2021-08-17
DOI
10.14802/jmd.21035
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms
- (2021) Xiangpeng Ren et al. Frontiers in Neuroscience
- Activation of Astrocytes in the Dorsomedial Striatum Facilitates Transition from Habitual to Goal-Directed Reward-Seeking Behavior
- (2020) Seungwoo Kang et al. BIOLOGICAL PSYCHIATRY
- The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease
- (2020) Jiang-Fan Chen et al. Purinergic Signalling
- Astrocyte adenosine signaling and neural mechanisms of goal-directed and habitual reward-seeking behaviors
- (2020) Seungwoo Kang et al. NEUROPSYCHOPHARMACOLOGY
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease
- (2019) Dilan Athauda et al. JAMA Neurology
- Indirect medium spiny neurons in the dorsomedial striatum regulate ethanol-containing conditioned reward seeking
- (2019) Sa-Ik Hong et al. JOURNAL OF NEUROSCIENCE
- Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
- (2019) Anastasia-Stefania Alexopoulos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
- (2019) Yazhou Li et al. Scientific Reports
- Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist
- (2018) Jaume Taura et al. JOURNAL OF CONTROLLED RELEASE
- Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia
- (2018) Annalisa Pinna et al. JOURNAL OF NEURAL TRANSMISSION
- Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum
- (2018) Yanan Luan et al. Frontiers in Neuroscience
- Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
- (2018) Jiyue Zheng et al. ACS Chemical Neuroscience
- Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?
- (2018) Margherita Torti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
- (2018) Shuchun Chen et al. Scientific Reports
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
- (2018) Delphine Charvin et al. NATURE REVIEWS DRUG DISCOVERY
- PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
- (2018) Fabiana Núñez et al. Frontiers in Pharmacology
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Comment: Caffeine and PD—Time to consider other interventions
- (2017) Charles B. Hall NEUROLOGY
- Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
- (2017) Fabrizio Stocchi et al. NEUROLOGY
- The Parkinson’s disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo
- (2017) Xavier Morató et al. Scientific Reports
- GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
- (2017) Rodrigo Carlessi et al. Scientific Reports
- Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches
- (2017) Luiza R. Nazario et al. Frontiers in Neuroscience
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
- (2017) Philip A Levin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease
- (2016) Annalisa Pinna et al. MOVEMENT DISORDERS
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- The incretin hormone GLP-1 and mechanisms underlying its secretion
- (2016) Lili Tian et al. Journal of Diabetes
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
- (2015) Kristy M. Heppner et al. ENDOCRINOLOGY
- Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells
- (2015) Diego V. Bohórquez et al. JOURNAL OF CLINICAL INVESTIGATION
- Heteroreceptor Complexes and their Allosteric Receptor–Receptor Interactions as a Novel Biological Principle for Integration of Communication in the CNS: Targets for Drug Development
- (2015) Kjell Fuxe et al. NEUROPSYCHOPHARMACOLOGY
- The Aversive Agent Lithium Chloride Suppresses Phasic Dopamine Release Through Central GLP-1 Receptors
- (2015) Samantha M Fortin et al. NEUROPSYCHOPHARMACOLOGY
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
- (2014) Annalisa Pinna CNS DRUGS
- Is insulin the most effective injectable antihyperglycaemic therapy?
- (2014) J. B. Buse et al. DIABETES OBESITY & METABOLISM
- Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
- (2014) Trevor W. Robbins et al. MOVEMENT DISORDERS
- Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b
- (2014) Izaskun Villar-Menéndez et al. NEUROBIOLOGY OF DISEASE
- Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion
- (2014) Ghupurjan Gheni et al. Cell Reports
- Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
- (2014) Thomas J. Moore et al. JAMA Internal Medicine
- GLP-1: benefits beyond pancreas
- (2014) G. Muscogiuri et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Regulation of Fear Responses by Striatal and Extrastriatal Adenosine A2A Receptors in Forebrain
- (2013) Catherine J. Wei et al. BIOLOGICAL PSYCHIATRY
- Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
- (2013) P. Richards et al. DIABETES
- Istradefylline: First Global Approval
- (2013) Rosselle Dungo et al. DRUGS
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
- (2013) Christian Hölscher JOURNAL OF ENDOCRINOLOGY
- Adenosine Transporter ENT1 Regulates the Acquisition of Goal-Directed Behavior and Ethanol Drinking through A2A Receptor in the Dorsomedial Striatum
- (2013) H. W. Nam et al. JOURNAL OF NEUROSCIENCE
- A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (Syn-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa
- (2013) R.A. Hauser et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
- (2013) Stewart A. Factor et al. MOVEMENT DISORDERS
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders
- (2013) Nikolaus R. McFarland et al. Neurodegenerative Diseases
- l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus
- (2013) Jordi Bonaventura et al. NEUROPHARMACOLOGY
- Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex
- (2013) Takako Kadowaki Horita et al. PSYCHOPHARMACOLOGY
- Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease
- (2013) Nandakumar S. Narayanan et al. REVIEWS IN THE NEUROSCIENCES
- Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum
- (2012) Pierre Trifilieff et al. BIOTECHNIQUES
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
- (2012) Antoni Vallano et al. CNS & Neurological Disorders-Drug Targets
- Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
- (2012) Per Svenningsson et al. LANCET NEUROLOGY
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- Implication of the Purinergic System in Alcohol Use Disorders
- (2011) Liana Asatryan et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- The gut-brain axis: a major glucoregulatory player
- (2011) R. Burcelin DIABETES & METABOLISM
- Selective inactivation of adenosine A2A receptors in striatal neurons enhances working memory and reversal learning
- (2011) C. J. Wei et al. LEARNING & MEMORY
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R
- (2010) Dasiel O. Borroto-Escuela et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Adenosine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
- (2010) K. Fuxe et al. CNS Neuroscience & Therapeutics
- Adenosine signaling and function in glial cells
- (2009) D Boison et al. CELL DEATH AND DIFFERENTIATION
- A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease
- (2009) Katia Varani et al. FASEB JOURNAL
- Metabotropic glutamate type 5, dopamine D2and adenosine A2areceptors form higher-order oligomers in living cells
- (2009) Nuria Cabello et al. JOURNAL OF NEUROCHEMISTRY
- Genetic Deletion of A2A Adenosine Receptors in the Striatum Selectively Impairs Habit Formation
- (2009) C. Yu et al. JOURNAL OF NEUROSCIENCE
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Glucagon-Like Peptide-1 Induced Signaling and Insulin Secretion Do Not Drive Fuel and Energy Metabolism in Primary Rodent Pancreatic β-Cells
- (2009) Marie-Line Peyot et al. PLoS One
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
- Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies
- (2007) Reinaldo Naoto Takahashi Frontiers in Bioscience-Landmark
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started